Efficacy and Safety of Programmed Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC: A Prospective Observational Study

Introduction: To date, the efficacy and safety of programmed death-ligand 1 (PD-L1) inhibitor plus platinum-etoposide chemotherapy for patients with extensive-stage SCLC (ES-SCLC), with real-world evidence, stratified on the basis of age and performance status (PS), have not been fully investigated....

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Kenji Morimoto, MD, PhD, Tadaaki Yamada, MD, PhD, Takayuki Takeda, MD, PhD, Shinsuke Shiotsu, MD, Koji Date, MD, Taishi Harada, MD, Nobuyo Tamiya, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Hibiki Kanda, MD, Takayuki Nakano, PhD, Yoshie Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Koichi Takayama, MD, PhD
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	Elsevier 2022-07-01
श्रृंखला:	JTO Clinical and Research Reports
विषय:	Extensive-stage small-cell lung cancer Elderly Chemoimmunotherapy Poor performance status Cancer cachexia
ऑनलाइन पहुंच:	http://www.sciencedirect.com/science/article/pii/S2666364322000777
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!